Cancer Family
Connective and Soft Tissue Neoplasm
CI-CAN-00000010Explore in graph →
Non-malignant849 active trials17 approved drugs339 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000010Explore in graph →
Clinical trials
3,878 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03241745 | A Study of Nivolumab in Selected Uterine Cancer Patients | completed | Phase 2 | 35 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT03997968 | A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 169 | Cyteir Therapeutics, Inc.INDUSTRY | 1 | Dec 24, 2024 | clinicaltrials |
| NCT06126510 |
| Clinical Study of VG161 in the Treatment of Advanced Bone and Soft Tissue Sarcoma |
| recruiting |
| Phase 2 |
| 40 |
| CNBG-Virogin Biotech (Shanghai) Ltd.INDUSTRY |
| 1 |
| Dec 24, 2024 |
| clinicaltrials |
| NCT06684327 | Multi-cohort, Single-arm Phase II Study of Albumin-paclitaxel, Ifosfamide, and Cisplatin in the Treatment of Rare Advanced Tumors | recruiting | Phase 2 | 100 | Fudan UniversityOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT03809637 | A Study of Pemetrexed Plus Cisplatin in Patients With Refractory Soft Tissue Sarcoma | completed | Phase 2 | 37 | Yonsei UniversityOTHER | 1 | Dec 18, 2024 | clinicaltrials |
| NCT06115408 | Evaluation of Using Dienogest and N-Acetyl Cysteine on the Volume of Uterine Leiomyoma | completed | Phase 2 / Phase 3 | 40 | Ain Shams UniversityOTHER | 1 | Dec 16, 2024 | clinicaltrials |
| NCT03233204 | Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 2 | Dec 11, 2024 | clinicaltrials |
| NCT04996004 | A Study to Learn About the Study Medicine (Called Ontorpacept or TTI-621) Given Alone and in Combination With Doxorubicin in People With Leiomyosarcoma(TTI-621-03) | terminated | Phase 2 | 76 | PfizerINDUSTRY | 1 | Dec 11, 2024 | clinicaltrials |
| NCT05017103 | Sintilimab for the Treatment of Locally Advanced, Metastatic, Recurrent, or Unresectable Undifferentiated Pleomorphic Sarcoma, SiARa Cancer Study | terminated | Phase 2 | 6 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 11, 2024 | clinicaltrials |
| NCT01291420 | Dendritic Cell Vaccination for Patients with Solid Tumors | completed | Phase 1 / Phase 2 | 48 | University Hospital, AntwerpOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT03023124 | Study With Trabectedin Versus Adriamycin Plus Dacarbazine, in Patients With Advanced Solitary Fibrous Tumor(STRADA) | completed | Phase 2 | 23 | Italian Sarcoma GroupNETWORK | 1 | Dec 9, 2024 | clinicaltrials |
| NCT04963517 | Exercise Intervention for Bone Tumor Patients(proGAIT) | completed | Phase 2 / Phase 3 | 11 | Universität Duisburg-EssenOTHER | 1 | Dec 6, 2024 | clinicaltrials |
| NCT03838744 | Randomized Trial in Advanced, Metastatic or Unresectable Soft Tissue Sarcoma After Failure of Standard Treatments.(TOMAS2) | completed | Phase 2 | 130 | Italian Sarcoma GroupNETWORK | 1 | Dec 4, 2024 | clinicaltrials |
| NCT06714383 | Trilaciclib Combing Chemotherapy in the Neoadjuvant Treatment of Osteosarcoma | recruiting | Phase 2 | 50 | Peking University People's HospitalOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT03148275 | Trametinib in Treating Patients With Epithelioid Hemangioendothelioma That is Metastatic, Locally Advanced, or Cannot Be Removed by Surgery | completed | Phase 2 | 44 | National Cancer Institute (NCI)NIH | 1 | Nov 26, 2024 | clinicaltrials |
| NCT05824975 | A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08) | recruiting | Phase 1 / Phase 2 | 358 | GI Innovation, Inc.INDUSTRY | 2 | Nov 25, 2024 | clinicaltrials |
| NCT06699472 | A Prospective, Randomized, Controlled Clinical Study on the Prevention of Chemotherapy Related Myelosuppression in Patients with Ewing's Sarcoma Using Trilaciclib | recruiting | Phase 2 | 22 | Fudan UniversityOTHER | 1 | Nov 21, 2024 | clinicaltrials |
| NCT03250325 | Study of TBI-1301 (NY-ESO-1 T Cell Receptor Gene Transduced Autologous T Lymphocytes) in Patients with Synovial Sarcoma | completed | Phase 1 / Phase 2 | 8 | Takara Bio Inc.INDUSTRY | 1 | Nov 20, 2024 | clinicaltrials |
| NCT06694324 | First-line Treatment of Advanced/unresectable DDLPS | not yet recruiting | Phase 2 | 49 | Fudan UniversityOTHER | 1 | Nov 19, 2024 | clinicaltrials |
| NCT06217536 | Neoadjuvant Lurbinectedin and Preoperative Radiation for Treating Soft Tissue Sarcomas | withdrawn | Phase 1 / Phase 2 | 0 | University of California, San FranciscoOTHER | 0 | Nov 18, 2024 | clinicaltrials |
| NCT06684795 | FG001 in Subjects with Meningiomas or Presumed Low-Grade Gliomas Scheduled for Neurosurgery | unknown | Phase 2 | 40 | Rigshospitalet, DenmarkOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT01117844 | Proton Radiation For Meningiomas and Hemangiopericytomas | completed | Phase 1 / Phase 2 | 53 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT06677853 | Timolol Maleate Gel for the Treatment of Infantile Hemangioma | completed | Phase 2 / Phase 3 | 168 | Auson Pharmaceuticals Inc.INDUSTRY | 1 | Nov 7, 2024 | clinicaltrials |
| NCT06640582 | TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas(BAH2472) | recruiting | Phase 1 / Phase 2 | 85 | Essen BiotechOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT03116529 | Neoadjuvant Durvalumab and Tremelimumab Plus Radiation for High Risk Soft-Tissue Sarcoma(NEXIS) | terminated | Phase 1 / Phase 2 | 22 | University of Maryland, BaltimoreOTHER | 1 | Nov 4, 2024 | clinicaltrials |
| NCT04873375 | Cemiplimab for Secondary Angiosarcomas | completed | Phase 2 | 18 | Radboud University Medical CenterOTHER | 1 | Oct 31, 2024 | clinicaltrials |
| NCT04887298 | Study of Liposomal Annamycin for the Treatment of Subjects with Soft-Tissue Sarcomas (STS) with Pulmonary Metastases | completed | Phase 1 / Phase 2 | 36 | Moleculin Biotech, Inc.INDUSTRY | 1 | Oct 24, 2024 | clinicaltrials |
| NCT03345485 | Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.(EDO-S101) | completed | Phase 1 / Phase 2 | 71 | Mundipharma Research LimitedINDUSTRY | 5 | Oct 21, 2024 | clinicaltrials |
| NCT06647901 | Efficacy of ICG-based NIR Imaging in Intralesional Curettage of Giant Cell Tumors of Bone in Limbs: a Prospective, Single-center, Single-arm, Open Study | recruiting | Phase 1 / Phase 2 | 45 | Tang XiaodongOTHER | 1 | Oct 18, 2024 | clinicaltrials |
| NCT05012397 | Milademetan in Advanced/Metastatic Solid Tumors | terminated | Phase 2 | 40 | Rain Oncology IncINDUSTRY | 1 | Oct 17, 2024 | clinicaltrials |
| NCT06637007 | Phase II Clinical Trial of Chidamide Combined With AK112 for Second-line and Advanced Bone and Soft Tissue Sarcoma | recruiting | Phase 2 | 30 | Shanxi Province Cancer HospitalOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT03840772 | Eribulin in Advanced Solitary Fibrous Tumor(ERASING) | completed | Phase 2 | 16 | Italian Sarcoma GroupNETWORK | 1 | Sep 20, 2024 | clinicaltrials |
| NCT04166006 | A Phase II Study on Adjuvant Vaccination with Dendritic Cells Loaded with Autologous Tumor Homogenate in Resected Stage IV Rare Cancers.(RaC-Ad) | recruiting | Phase 2 | 51 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06593899 | The Total Neoadjuvant Therapy for Soft Tissue Sarcoma of the Extremities | unknown | Phase 2 | 51 | Fujian Medical University Union HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06438614 | A Study Of Naxitamab , Granulocyte Macrophage Colony Stimulating Factor For Patients With Relapsed /Refractory , Soft Tissue or Anti GD2 Immunotherapy Refractory Neuroblastoma(NICE) | completed | Phase 2 | 47 | Fundació Sant Joan de DéuOTHER | 1 | Aug 29, 2024 | clinicaltrials |
| NCT05830123 | ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas | recruiting | Phase 2 | 170 | Hansoh BioMedical R&D CompanyINDUSTRY | 1 | Aug 23, 2024 | clinicaltrials |
| NCT06564272 | A Study of KC1036 in Adolescents With Advanced Ewing Sarcoma | recruiting | Phase 2 | 30 | Beijing Konruns Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 23, 2024 | clinicaltrials |
| NCT00819169 | QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors | terminated | Phase 1 / Phase 2 | 89 | NantCell, Inc.INDUSTRY | 0 | Aug 20, 2024 | clinicaltrials |
| NCT01863745 | Nilotinib Roll-over Protocol for Patients in Novartis-sponsored Nilotinib Study and Benefiting From Nilotinib Treatment | completed | Phase 2 | 15 | Novartis PharmaceuticalsINDUSTRY | 1 | Aug 19, 2024 | clinicaltrials |
| NCT03277924 | Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas(ImmunoSarc) | completed | Phase 1 / Phase 2 | 197 | Grupo Espanol de Investigacion en SarcomasOTHER | 3 | Aug 13, 2024 | clinicaltrials |
| NCT06551896 | Pemigatinib and Immune Checkpoint Inhibitor Treated FGFR1/2/3 Alteration Advanced Solid Tumor | not yet recruiting | Phase 2 | 30 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 0 | Aug 13, 2024 | clinicaltrials |
| NCT02207309 | Pazopanib Maintenance Phase II | terminated | Phase 2 | 1 | Ludwig-Maximilians - University of MunichOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT06524778 | Single High-dose Brachytherapy for Giant Osteosarcoma Masses | not yet recruiting | Phase 2 | 16 | Shanghai Jiao Tong University Affiliated Sixth People's HospitalOTHER | 0 | Aug 7, 2024 | clinicaltrials |
| NCT01294202 | A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST | completed | Phase 2 | 26 | Astex Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 2, 2024 | clinicaltrials |
| NCT04129151 | Palbociclib + Ganitumab In Ewing Sarcoma | terminated | Phase 2 | 10 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 1, 2024 | clinicaltrials |
| NCT03338959 | Pembrolizumab and Radiation Therapy in Treating Patients With Intermediate or High-Grade Soft Tissue Sarcoma | completed | Phase 1 / Phase 2 | 27 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 23, 2024 | clinicaltrials |
| NCT06514313 | Clinical Trial of VIM With VIT in Children With Relapsed and Refractory Soft Tissue Sarcoma. | recruiting | Phase 2 | 110 | Yizhuo ZhangOTHER | 1 | Jul 23, 2024 | clinicaltrials |
| NCT02978859 | Sitravatinib in Advanced Liposarcoma and Other Soft Tissue Sarcomas | completed | Phase 2 | 29 | Columbia UniversityOTHER | 1 | Jul 18, 2024 | clinicaltrials |
| NCT00290251 | Treatment of Uterine Fibroids With the Selective Progesterone Receptor Modulator CDB-2914 | completed | Phase 2 | 72 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH | 1 | Jul 15, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Dec 27, 2024source: clinicaltrials